Chief Executive Pascal Soriot of British pharmaceutical company AstraZeneca Plc (STO:AZN)(LON:AZN) said that the company is still waiting for the go-ahead from the US drug regulator, the Federal Drug Administration (FDA), to restart the clinical trial of its potential COVID-19 vaccine in the US, Reuters news agency reported on Thursday.
Reportedly, the US trial of AstraZeneca's COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the US have resumed.
According to US Health and Human Services Secretary Alex Azar, this continued suspension showed the US FDA took vaccine safety seriously.
Oxford University has stated the illness in a British participant that triggered the trail pause on 6 September 2020 may not have been associated with the vaccine, Reuters added.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval